Journal of Clinical Oncology, Vol 15, 2553-2558, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin

H Xiao, M Mazumdar, DF Bajorin, M Sarosdy, V Vlamis, J Spicer, J Ferrara, GJ Bosl and RJ Motzer
Department of Medicine, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, NY, USA.

PURPOSE: To assess the durability of response and overall survival for patients with good-risk metastatic germ cell tumors (GCT) treated with four cycles of etoposide and cisplatin (EP). PATIENTS AND METHODS: Two hundred fourteen patients treated with EP on two consecutive randomized trials for good-risk metastatic GCT were the subject of this retrospective study. The response to therapy, relapse and survival status, and results of salvage therapy are reported. RESULTS: One hundred ninety-five patients (91%) achieved a complete response (CR). This included 182 patients (85%) who achieved a CR to chemotherapy alone and 13 patients (6%) who achieved a CR to chemotherapy plus surgical resection of viable GCT. Seventeen patients (9%) have relapsed from CR. The median time to relapse was 10 months, and the longest duration from treatment to relapse was 36 months in a patient who received three of four planned courses of therapy. Eight patients who either achieved an incomplete response (IR) or relapsed were rendered continuously disease-free by salvage therapy and are alive. One hundred eighty-three patients (86%) are alive at a median follow-up of 7.6 years. CONCLUSION: Four cycles of EP constitute effective therapy and can be offered to patients with good-risk GCT. In patients with intermediate- and poor-risk GCT, clinical trials remain a priority to identify more effective treatment.

This article has been cited by other articles:

				R. de Wit Refining the Optimal Chemotherapy Regimen in Good Prognosis Germ Cell Cancer: Interpretation of the Current Body of Knowledge J. Clin. Oncol., October 1, 2007; 25(28): 4346 - 4349. [Full Text] [PDF]

				L. H. Einhorn and R. S. Foster Bleomycin, Etoposide, and Cisplatin for Three Cycles Compared With Etoposide and Cisplatin for Four Cycles in Good-Risk Germ Cell Tumors: Is There a Preferred Regimen? J. Clin. Oncol., June 1, 2006; 24(16): 2597 - 2598. [Full Text] [PDF]

				G. V. Kondagunta, J. Bacik, D. Bajorin, D. Dobrzynski, J. Sheinfeld, R. J. Motzer, and G. J. Bosl Etoposide and Cisplatin Chemotherapy for Metastatic Good-Risk Germ Cell Tumors J. Clin. Oncol., December 20, 2005; 23(36): 9290 - 9294. [Abstract] [Full Text] [PDF]

				H. J. Schmoll, R. Souchon, S. Krege, P. Albers, J. Beyer, C. Kollmannsberger, S. D. Fossa, N. E. Skakkebaek, R. de Wit, K. Fizazi, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG) Ann. Onc., September 1, 2004; 15(9): 1377 - 1399. [Abstract] [Full Text] [PDF]

				G. V. Kondagunta, J. Sheinfeld, M. Mazumdar, T. V. Mariani, D. Bajorin, J. Bacik, G. J. Bosl, and R. J. Motzer Relapse-Free and Overall Survival in Patients With Pathologic Stage II Nonseminomatous Germ Cell Cancer Treated With Etoposide and Cisplatin Adjuvant Chemotherapy J. Clin. Oncol., February 1, 2004; 22(3): 464 - 467. [Abstract] [Full Text] [PDF]

				F. Rabbani, J. Sheinfeld, H. Farivar-Mohseni, A. Leon, M. J. Rentzepis, V. E. Reuter, H. W. Herr, J. A. McCaffrey, R. J. Motzer, D. F. Bajorin, et al. Low-Volume Nodal Metastases Detected at Retroperitoneal Lymphadenectomy for Testicular Cancer: Pattern and Prognostic Factors for Relapse J. Clin. Oncol., April 1, 2001; 19(7): 2020 - 2025. [Abstract] [Full Text] [PDF]

				R. J. Motzer, J. Sheinfeld, M. Mazumdar, M. Bains, T. Mariani, J. Bacik, D. Bajorin, and G. J. Bosl Paclitaxel, Ifosfamide, and Cisplatin Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Cancer J. Clin. Oncol., June 12, 2000; 18(12): 2413 - 2418. [Abstract] [Full Text] [PDF]